Trial watch: Dendritic cell-based anticancer immunotherapy.

摘要: Dendritic cell (DC)-based vaccines against cancer have been extensively developed over the past two decades. Typically DC-based immunotherapy entails loading patient-derived DCs with an appropriate source of tumor-associated antigens (TAAs) and efficient DC stimulation through a so-called "maturation cocktail" (typically combination pro-inflammatory cytokines Toll-like receptor agonists), followed by reintroduction into patients. documented to (re)activate tumor-specific T cells in both preclinical clinical settings. There is considerable interest combining anticancer cell-targeting immunotherapies. This reflects established capacity generate pool TAA-specific effector facilitate their infiltration tumor bed. In this Trial Watch, we survey latest trends development therapeutics. We also highlight how emergence immune checkpoint blockers adoptive T-cell transfer-based approaches has modified niche for within wide landscape.